STOCKHOLM — New data on a needle-free nasal delivery system for glucagon for use in severe hypoglycemia presented at the European Association for the Study of Diabetes (EASD) 2015 Meeting here today ...

Please provide your email address to receive an email when new articles are posted on . Nasal glucagon was noninferior to intramuscular glucagon for treating hypoglycemia in Japanese adults with type ...

(HealthDay News) — Nasal glucagon can effectively and efficiently manage moderate or severe hypoglycemic episodes (HEs) in real-world settings in adult patients with type 1 diabetes, according to a ...

There’s some new guidance on treating hypoglycemia, or low blood sugar, in long-term care communities. It’s specifically geared for healthcare workers, though anyone who is a caregiver for someone ...

RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated ...

Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of prescribing glucagon, positioning the partners to address a fundamental barrier ...

Please provide your email address to receive an email when new articles are posted on . Fewer people with diabetes filled glucagon prescriptions in 2021 compared with 2011, though increases were seen ...

Amphastar Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company known for developing, manufacturing, and ...